Literature DB >> 10835998

The management of pain in sickle cell disease.

M Yaster1, S Kost-Byerly, L G Maxwell.   

Abstract

The pain of vaso-occlusive crisis in patients with sickle cell disease is excruciating, incapacitating, and sometimes refractory to even the most advanced analgesic treatments. A comprehensive, multimodal approach to therapy that includes education, cognitive therapies, anti-inflammatory drugs, opioids, and psychostimulant adjuvant drugs has been presented. Until a cure for the underlying disease is found, these are the best approaches available. The authors hope that future research will find even better modalities of analgesic care.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10835998     DOI: 10.1016/s0031-3955(05)70233-9

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  5 in total

1.  Increased clearance of morphine in sickle cell disease: implications for pain management.

Authors:  Deepika S Darbari; Michael Neely; John van den Anker; Sohail Rana
Journal:  J Pain       Date:  2011-02-01       Impact factor: 5.820

2.  Association between elevated depressive symptoms and clinical disease severity in African-American adults with sickle cell disease.

Authors:  Brian Laurence; David George; Dexter Woods
Journal:  J Natl Med Assoc       Date:  2006-03       Impact factor: 1.798

Review 3.  Pain management in children with sickle cell disease.

Authors:  Jennifer Stinson; Basem Naser
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

4.  Magnesium for treating sickle cell disease.

Authors:  Nan Nitra Than; Htoo Htoo Kyaw Soe; Senthil K Palaniappan; Adinegara Bl Abas; Lucia De Franceschi
Journal:  Cochrane Database Syst Rev       Date:  2019-09-09

5.  Observations on the management of acute pain crisis in adult sickle cell disease in eastern Saudi Arabia.

Authors:  Emmanuel Udezue; Abdel Moneim Girshab
Journal:  Ann Saudi Med       Date:  2005 Mar-Apr       Impact factor: 1.526

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.